Immunological response and temporal associations in myocarditis after COVID-19 vaccination using cardiac magnetic resonance imaging : An amplified T-cell response at the heart of it?
Copyright © 2022 Vago, Szabo, Szabo, Ulakcsai, Szogi, Budai, Toth, Juhasz, Dohy, Hoffer, Becker, Kiss, Nagy, Nagy and Merkely..
Introduction: Although myocarditis after anti-SARS-CoV-2 vaccination is increasingly recognized, we have little data regarding the course of the disease and, consequently, the imaging findings, including the tissue-specific features. The purpose of this study is to describe the clinical, immunological, and cardiac magnetic resonance (CMR) features of myocarditis after COVID-19 immunization in the acute phase and during follow-up. We aimed to compare the trajectory of the disease to myocarditis cases unrelated to COVID-19.
Methods: We assembled a CMR-based registry of potentially COVID-19 vaccination-related myocarditis cases. All patients who experienced new-onset chest pain and troponin elevation after COVID-19 vaccination and imaging confirming the clinical suspicion of acute myocarditis were enrolled in our study. Participants underwent routine laboratory testing and testing of their humoral and cellular immune response to COVID-19 vaccination. Clinical and CMR follow-up was performed after 3-6 months. We included two separate, sex- and age-matched control groups: (1) individuals with myocarditis unrelated to COVID-19 infection or vaccination confirmed by CMR and (2) volunteers with similar immunological exposure to SARS-CoV-2 compared to our group of interest (no difference in the number of doses, types and the time since anti-SARS-CoV-2 vaccination and no difference in anti-nucleocapsid levels).
Results: We report 16 CMR-confirmed cases of myocarditis presenting (mean ± SD) 4 ± 2 days after administration of the anti-SARS-CoV-2 vaccine (male patients, 22 ± 7 years), frequently with predisposing factors such as immune-mediated disease and previous myocarditis. We found that 75% received mRNA vaccines, and 25% received vector vaccines. During follow-up, CMR metrics depicting myocardial injury, including oedema and necrosis, decreased or completely disappeared. There was no difference regarding the CMR metrics between myocarditis after immunization and myocarditis unrelated to COVID-19. We found an increased T-cell response among myocarditis patients compared to matched controls (p < 0.01), while there was no difference in the humoral immune response.
Conclusion: In our cohort, myocarditis occurred after both mRNA and vector anti-SARS-CoV-2 vaccination, frequently in individuals with predisposing factors. Upon follow-up, the myocardial injury had healed. Notably, an amplified cellular immune response was found in acute myocarditis cases occurring 4 days after COVID-19 vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Frontiers in cardiovascular medicine - 9(2022) vom: 25., Seite 961031 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vago, Hajnalka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular magnetic resonance |
|---|
| Anmerkungen: |
Date Revised 04.10.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fcvm.2022.961031 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347024580 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347024580 | ||
| 003 | DE-627 | ||
| 005 | 20231226032838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcvm.2022.961031 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM347024580 | ||
| 035 | |a (NLM)36186968 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vago, Hajnalka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunological response and temporal associations in myocarditis after COVID-19 vaccination using cardiac magnetic resonance imaging |b An amplified T-cell response at the heart of it? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.10.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Vago, Szabo, Szabo, Ulakcsai, Szogi, Budai, Toth, Juhasz, Dohy, Hoffer, Becker, Kiss, Nagy, Nagy and Merkely. | ||
| 520 | |a Introduction: Although myocarditis after anti-SARS-CoV-2 vaccination is increasingly recognized, we have little data regarding the course of the disease and, consequently, the imaging findings, including the tissue-specific features. The purpose of this study is to describe the clinical, immunological, and cardiac magnetic resonance (CMR) features of myocarditis after COVID-19 immunization in the acute phase and during follow-up. We aimed to compare the trajectory of the disease to myocarditis cases unrelated to COVID-19 | ||
| 520 | |a Methods: We assembled a CMR-based registry of potentially COVID-19 vaccination-related myocarditis cases. All patients who experienced new-onset chest pain and troponin elevation after COVID-19 vaccination and imaging confirming the clinical suspicion of acute myocarditis were enrolled in our study. Participants underwent routine laboratory testing and testing of their humoral and cellular immune response to COVID-19 vaccination. Clinical and CMR follow-up was performed after 3-6 months. We included two separate, sex- and age-matched control groups: (1) individuals with myocarditis unrelated to COVID-19 infection or vaccination confirmed by CMR and (2) volunteers with similar immunological exposure to SARS-CoV-2 compared to our group of interest (no difference in the number of doses, types and the time since anti-SARS-CoV-2 vaccination and no difference in anti-nucleocapsid levels) | ||
| 520 | |a Results: We report 16 CMR-confirmed cases of myocarditis presenting (mean ± SD) 4 ± 2 days after administration of the anti-SARS-CoV-2 vaccine (male patients, 22 ± 7 years), frequently with predisposing factors such as immune-mediated disease and previous myocarditis. We found that 75% received mRNA vaccines, and 25% received vector vaccines. During follow-up, CMR metrics depicting myocardial injury, including oedema and necrosis, decreased or completely disappeared. There was no difference regarding the CMR metrics between myocarditis after immunization and myocarditis unrelated to COVID-19. We found an increased T-cell response among myocarditis patients compared to matched controls (p < 0.01), while there was no difference in the humoral immune response | ||
| 520 | |a Conclusion: In our cohort, myocarditis occurred after both mRNA and vector anti-SARS-CoV-2 vaccination, frequently in individuals with predisposing factors. Upon follow-up, the myocardial injury had healed. Notably, an amplified cellular immune response was found in acute myocarditis cases occurring 4 days after COVID-19 vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 immunization | |
| 650 | 4 | |a cardiovascular magnetic resonance | |
| 650 | 4 | |a immunological response | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Szabo, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Szabo, Zsofia |e verfasserin |4 aut | |
| 700 | 1 | |a Ulakcsai, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Szogi, Emese |e verfasserin |4 aut | |
| 700 | 1 | |a Budai, Gizella |e verfasserin |4 aut | |
| 700 | 1 | |a Toth, Attila |e verfasserin |4 aut | |
| 700 | 1 | |a Juhasz, Vencel |e verfasserin |4 aut | |
| 700 | 1 | |a Dohy, Zsofia |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffer, Krisztina |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss, Robert Gabor |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Gergely Gyorgy |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Gyorgy |e verfasserin |4 aut | |
| 700 | 1 | |a Merkely, Bela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cardiovascular medicine |d 2014 |g 9(2022) vom: 25., Seite 961031 |w (DE-627)NLM255534736 |x 2297-055X |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g day:25 |g pages:961031 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcvm.2022.961031 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |b 25 |h 961031 | ||